• 1
    Meier-Kriesche HU, Schold JD and Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289.
  • 2
    Libby P, Pober JS. Chronic rejection. Immunity 2001; 14: 387.
  • 3
    Billingham RE, Brent L, Medawar PB. Activity acquired tolerance of foreign cells. Nature 1953; 172: 603.
  • 4
    Auchincloss Jr H. In search of the elusive Holy Grail: the mechanisms and prospects for achieving clinical transplantation tolerance. Am J Transplant 2001; 1: 6.
  • 5
    Kirk AD. Immunosuppression without immunosuppression? How to be a tolerant individual in a dangerous world. Transpl Infect Dis 1999; 1: 65.
  • 6
    Morelli AE, Thomson AW. Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol Rev 2003; 196: 125.
  • 7
    Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685.
  • 8
    Mirenda V, Berton I, Read J, et al. Modified dendritic cells coexpressing self and allogeneic major histocompatibility complex molecules: an efficient way to induce indirect pathway regulation. J Am Soc Nephrol 2004; 15: 987.
  • 9
    Rice AM, Jones KL, Hart DN. DC preparations for therapy. Cytotherapy 2004; 6: 99.
  • 10
    Morelli AE, Wong Z, Larregina AT, et al. In situ targeting of recipient dendritic cells with donor early apoptotic cells prolongs allograft survival by inducing deficient activation followed by deletion of alloreactive T cells. Am J Transplant 2005; 565: 1609.
  • 11
    Albert ML, Pearce SF, Francisco LM, et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188: 1359.
  • 12
    Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392: 86.
  • 13
    Adler AJ, Marsh DW, Yochum GS, et al. CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J Exp Med 1998; 187: 1555.
  • 14
    Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000; 191: 411.
  • 15
    Harshyne LA, Watkins SC, Gambotto A, Barratt-Boyes SM. Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J Immunol 2001; 166: 3717.
  • 16
    Rouhiainen A, Kuja-Panula J, Wilkman E, et al. Regulation of monocyte migration by amphoterin (HMGB1). Blood 2004; 104: 1174.
  • 17
    Rovere-Querini P, Capobianco A, Scaffidi P, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004; 5: 825.
  • 18
    Messmer D, Yang H, Telusma G, et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004; 173: 307.
  • 19
    Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 2000; 12: 1539.
  • 20
    Tsan MF, Gao B. Cytokine function of heat shock proteins. Am J Physiol Cell Physiol 2004; 286: C739.
  • 21
    Wan T, Zhou X, Chen G, et al. Novel heat shock protein Hsp70L1 activates dendritic cells and acts as a Th1 polarizing adjuvant. Blood 2004; 103: 1747.
  • 22
    Pulendran B. Immune activation: death, danger and dendritic cells. Curr Biol 2004; 14: R30.
  • 23
    Schnurr M, Toy T, Stoitzner P, et al. ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling. Blood 2003; 102: 613.
  • 24
    Nacken W, Roth J, Sorg C, Kerkhoff C. S100A9/S100A8: myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc Res Tech 2003; 60: 569.
  • 25
    Lechler RI, Garden OA, Turka LA. The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol 2003; 3: 147.
  • 26
    Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 2001; 166: 973.
  • 27
    Jeffery JR, Guttmann RD, Charpentier B. In vitro monitoring of cadaver kidney donor pretreatment by lymphocyte culture. Clin Exp Immunol 1976; 25: 437.
  • 28
    Lechler RI, Batchelor JR. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med 1982; 155: 31.
  • 29
    Talmage DW, Dart G, Radovich J, Lafferty KJ. Activation of transplant immunity: effect of donor leukocytes on thyroid allograft rejection. Science 1976; 191: 385.
  • 30
    Larsen CP, Morris PJ, Austyn JM. Migration of dendritic leukocytes from cardiac allografts into host spleens. A novel pathway for initiation of rejection. J Exp Med 1990; 171: 307.
  • 31
    Larsen CP, Steinman RM, Witmer-Pack M, Hankins DF, Morris PJ, Austyn JM. Migration and maturation of Langerhans cells in skin transplants and explants. J Exp Med 1990; 172: 1483.
  • 32
    Starzl TE, Demetris AJ, Murase N, Trucco M, Thomson AW, Rao AS. The lost chord: microchimerism and allograft survival. Immunol Today 1996; 17: 577.
  • 33
    Starzl TE, Zinkernagel RM. Antigen localization and migration in immunity and tolerance. N Engl J Med 1998; 339: 1905.
  • 34
    Thomson AW, Lu L, Murase N, Demetris AJ, Rao AS, Starzl TE. Microchimerism, dendritic cell progenitors and transplantation tolerance. Stem Cells 1995; 13: 622.
  • 35
    Suciu-Foca N, Ciubotariu R, Colovai A, et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection. Transplant Proc 1999; 31: 100.
  • 36
    Mason PD, Robinson CM, Lechler RI. Detection of donor-specific hyporesponsiveness following late failure of human renal allografts. Kidney Int 1996; 50: 1019.
  • 37
    Hornick PI, Mason PD, Yacoub MH, Rose ML, Batchelor R, Lechler RI. Assessment of the contribution that direct allorecognition makes to the progression of chronic cardiac transplant rejection in humans. Circulation 1998; 97: 1257.
  • 38
    Liu Z, Colovai AI, Tugulea S, et al. Indirect recognition of donor HLA-DR peptides in organ allograft rejection. J Clin Invest 1996; 98: 1150.
  • 39
    Reznik SI, Jaramillo A, SivaSai KS, et al. Indirect allorecognition of mismatched donor HLA class II peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Am J Transplant 2001; 1: 228.
  • 40
    SivaSai KS, Smith MA, Poindexter NJ, et al. Indirect recognition of donor HLA class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Transplantation 1999; 67: 1094.
  • 41
    Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003; 3: 665.
  • 42
    Jenkinson EJ, Jhittay P, Kingston R, Owen JJ. Studies of the role of the thymic environment in the induction of tolerance to MHC antigens. Transplantation 1985; 39: 331.
  • 43
    Matzinger P, Guerder S. Does T-cell tolerance require a dedicated antigen-presenting cell? Nature 1989; 338: 74.
  • 44
    Inaba M, Inaba K, Hosono M, et al. Distinct mechanisms of neonatal tolerance induced by dendritic cells and thymic B cells. J Exp Med 1991; 173: 549.
  • 45
    Gao EK, Lo D, Sprent J. Strong T cell tolerance in parent [RIGHTWARDS ARROW] F1 bone marrow chimeras prepared with supralethal irradiation. Evidence for clonal deletion and anergy. J Exp Med 1990; 171: 1101.
  • 46
    Widera G, Burkly LC, Pinkert CA, et al. Transgenic mice selectively lacking MHC class II (I-E) antigen expression on B cells: an in vivo approach to investigate Ia gene function. Cell 1987; 51: 175.
  • 47
    Oluwole SF, Jin MX, Chowdhury NC, Engelstad K, Ohajekwe OA, James T. Induction of peripheral tolerance by intrathymic inoculation of soluble alloantigens: evidence for the role of host antigen-presenting cells and suppressor cell mechanism. Cell Immunol 1995; 162: 33.
  • 48
    Ali A, Garrovillo M, Jin MX, Hardy MA, Oluwole SF. Major histocompatibility complex class I peptide-pulsed host dendritic cells induce antigen-specific acquired thymic tolerance to islet cells. Transplantation 2000; 69: 221.
  • 49
    Garrovillo M, Ali A, Oluwole SF. Indirect allorecognition in acquired thymic tolerance: induction of donor-specific tolerance to rat cardiac allografts by allopeptide-pulsed host dendritic cells. Transplantation 1999; 68: 1827.
  • 50
    Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 2002; 99: 351.
  • 51
    Jenkins MK, Chen CA, Jung G, Mueller DL, Schwartz RH. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J Immunol 1990; 144: 16.
  • 52
    Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192: 1213.
  • 53
    Hawiger D, Inaba K, Dorsett Y, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194: 769.
  • 54
    Iyoda T, Shimoyama S, Liu K, et al. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med 2002; 195: 1289.
  • 55
    Ferguson TA, Herndon J, Elzey B, Griffith TS, Schoenberger S, Green DR. Uptake of apoptotic antigen-coupled cells by lymphoid dendritic cells and cross-priming of CD8(+) T cells produce active immune unresponsiveness. J Immunol 2002; 168: 5589.
  • 56
    Liu K, Iyoda T, Saternus M, Kimura Y, Inaba K, Steinman RM. Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 2002; 196: 1091.
  • 57
    Lu L, Bonham CA, Liang X, et al. Liver-derived DEC205+B220+CD19- dendritic cells regulate T cell responses. J Immunol 2001; 166: 7042.
  • 58
    Lechler R, Chai JG, Marelli-Berg F, Lombardi G. The contributions of T-cell anergy to peripheral T-cell tolerance. Immunology 2001; 103: 262.
  • 59
    Lu L, McCaslin D, Starzl TE, Thomson AW. Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7–1dim, B7–2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes. Transplantation 1995; 60: 1539.
  • 60
    Fu F, Li Y, Qian S, et al. Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation 1996; 62: 659.
  • 61
    Wang Z, Morelli AE, Hackstein H, Kaneko K, Thomson AW. Marked inhibition of transplant vascular sclerosis by in vivo-mobilized donor dendritic cells and anti-CD154 mAb. Transplantation 2003; 76: 562.
  • 62
    Lutz MB, Suri RM, Niimi M, et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol 2000; 30: 1813.
  • 63
    Lu L, Li W, Zhong C, et al. Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb. Transplantation 1999; 68: 747.
  • 64
    Hayamizu K, Huie P, Sibley RK, Strober S. Monocyte-derived dendritic cell precursors facilitate tolerance to heart allografts after total lymphoid irradiation. Transplantation 1998; 66: 1285.
  • 65
    Bonham CA, Peng L, Liang X, et al. Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J Immunol 2002; 169: 3382.
  • 66
    DePaz HA, Oluwole OO, Adeyeri AO, et al. Immature rat myeloid dendritic cells generated in low-dose granulocyte macrophage-colony stimulating factor prolong donor-specific rat cardiac allograft survival. Transplantation 2003; 75: 521.
  • 67
    Wang Q, Zhang M, Ding G, et al. Anti-ICAM-1 antibody and CTLA-4Ig synergistically enhance immature dendritic cells to induce donor-specific immune tolerance in vivo. Immunol Lett 2003; 90: 33.
  • 68
    Peche H, Trinite B, Martinet B, Cuturi MC. Prolongation of heart allograft survival by immature dendritic cells generated from recipient type bone marrow progenitors. Am J Transplant 2005; 5: 255.
  • 69
    Taner T, Hackstein H, Wang Z, Morelli AE, Thomson AW. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant 2005; 5: 228.
  • 70
    Garrovillo M, Ali A, Depaz HA, et al. Induction of transplant tolerance with immunodominant allopeptide-pulsed host lymphoid and myeloid dendritic cells. Am J Transplant 2001; 1: 129.
  • 71
    Tiao MM, Lu L, Tao R, Wang L, Fung JJ, Qian S. Prolongation of cardiac allograft survival by systemic administration of immature recipient dendritic cells deficient in NF-kappaB activity. Ann Surg 2005; 241: 497.
  • 72
    Beriou G, Peche H, Guillonneau C, Merieau E, Cuturi MC. Donor-specific allograft tolerance by administration of recipient-derived immature dendritic cells and suboptimal immunosuppression. Transplantation 2005; 79: 969.
  • 73
    Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193: 233.
  • 74
    Hackstein H, Thomson AW. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 2004; 4: 24.
  • 75
    Adorini L, Giarratana N, Penna G. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol 2004; 16: 127.
  • 76
    Matsue H, Yang C, Matsue K, Edelbaum D, Mummert M, Takashima A. Contrasting impacts of immunosuppressive agents (rapamycin, FK506, cyclosporin A, and dexamethasone) on bidirectional dendritic cell-T cell interaction during antigen presentation. J Immunol 2002; 169: 3555.
  • 77
    Hackstein H, Taner T, Zahorchak AF, et al. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003; 101: 4457.
  • 78
    Monti P, Allavena P, Di Carlo V, Piemonti L. Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol 2003; 3: 189.
  • 79
    Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 52.
  • 80
    Figdor CG, De Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10: 475.
  • 81
    Pham SM, Rao AS, Zeevi A, et al. A clinical trial combining donor bone marrow infusion and heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg 2000; 119: 673.
  • 82
    Pham SM, Rao AS, Zeevi A, et al. Effects of donor bone marrow infusion in clinical lung transplantation. Ann Thorac Surg 2000; 69: 345.
  • 83
    Salgaller ML. A manifesto on the current state of dendritic cells in adoptive immunotherapy. Transfusion 2003; 43: 422.
  • 84
    Gastineau DA. Will regulation be the death of cell therapy in the United States? Bone Marrow Transplant 2004; 33: 777.
  • 85
    Radcliff FJ, Caruso DA, Koina C, et al. Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy. Br J Haematol 2002; 119: 204.
  • 86
    Rutella S, Bonanno G, Pierelli L, et al. Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-alpha. Eur J Immunol 2004; 34: 1291.
  • 87
    Vela-Ojeda J, Esparza MA, Reyes-Maldonado E, et al. CD4+ CD25+ lymphocyte and dendritic cell mobilization with intermediate doses of recombinant human granulocyte colony-stimulating factor in healthy donors. Stem Cells Dev 2005; 14: 310.
  • 88
    Buggins AG, Mufti GJ, Salisbury J, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 2002; 100: 1715.
  • 89
    Klangsinsirikul P, Carter GI, Byrne JL, Hale G, Russell NH. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 2002; 99: 2586.
  • 90
    Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood 2003; 101: 1422.
  • 91
    Fang L, Fehse B, Engel M, Zander A, Kroger N. Antithymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells. Transplantation 2005; 79: 369.
  • 92
    Fallarino F, Asselin-Paturel C, Vacca C, et al. Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J Immunol 2004; 173: 3748.
  • 93
    Gorczynski RM, Chen Z, Kai Y, Wong S, Lee L. Induction of tolerance-inducing antigen-presenting cells in bone marrow cultures in vitro using monoclonal antibodies to CD200R. Transplantation 2004; 77: 1138.
  • 94
    Collin MP, Munster D, Clark G, Wang XN, Dickinson AM, Hart DN. In vitro depletion of tissue-derived dendritic cells by CMRF-44 antibody and alemtuzumab: implications for the control of Graft-versus-host disease. Transplantation 2005; 79: 722.
  • 95
    Baban B, Hansen AM, Chandler PR, et al. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int Immunol 2005; 17: 909.
  • 96
    Mellor AL, Chandler P, Baban B, et al. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int Immunol 2004; 16: 1391.
  • 97
    Munn DH, Sharma MD, Mellor AL. Ligation of B7–1/B7–2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 2004; 172: 4100.
  • 98
    Enk AH. Dendritic cells in tolerance induction. Immunol Lett 2005; 99: 8.
  • 99
    Strobl H, Knapp W. TGF-beta1 regulation of dendritic cells. Microbes Infect 1999; 1: 1283.
  • 100
    Ciesek S, Ringe BP, Strassburg CP, et al. Effects of cyclosporine on human dendritic cell subsets. Transplant Proc 2005; 37: 20.
  • 101
    Duperrier K, Velten FW, Bohlender J, Demory A, Metharom P, Goerdt S. Immunosuppressive agents mediate reduced allostimulatory properties of myeloid-derived dendritic cells despite induction of divergent molecular phenotypes. Mol Immunol 2005; 42: 1531.
  • 102
    Baumer W, Sulzle B, Weigt H, et al. Cilomilast, tacrolimus and rapamycin modulate dendritic cell function in the elicitation phase of allergic contact dermatitis. Br J Dermatol 2005; 153: 136.
  • 103
    Mainali ES, Kikuchi T, Tew JG. Dexamethasone inhibits maturation and alters function of monocyte-derived dendritic cells from cord blood. Pediatr Res 2005; 58: 125.
  • 104
    Abe M, Thomson AW. Dexamethasone preferentially suppresses plasmacytoid dendritic cell differentiation and enhances their apoptotic death. Clin Immunol 2006; 118: 300.
  • 105
    Zeyda M, Kirsch BM, Geyeregger R, et al. Inhibition of human dendritic cell maturation and function by the novel immunosuppressant FK778. Transplantation 2005; 80: 1105.
  • 106
    Muller H, Hofer S, Kaneider N, et al. The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol 2005; 35: 533.
  • 107
    Lan YY, De Creus A, Colvin BL, et al. The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo. Am J Transplant 2005; 5: 2649.
  • 108
    Carbonnelle D, Ebstein F, Rabu C, Petit JY, Gregoire M, Lang F. A new carboxamide compound exerts immuno-suppressive activity by inhibiting dendritic cell maturation. Eur J Immunol 2005; 35: 546.
  • 109
    Kim GY, Cho H, Ahn SC, Oh YH, Lee CM, Park YM. Resveratrol inhibits phenotypic and functional maturation of murine bone marrow-derived dendritic cells. Int Immunopharmacol 2004; 4: 245.
  • 110
    Woltman AM, Schlagwein N, Van Der Kooij SW, Van Kooten C. The novel cyclophilin-binding drug sanglifehrin A specifically affects antigen uptake receptor expression and endocytic capacity of human dendritic cells. J Immunol 2004; 172: 6482.
  • 111
    Thoeni G, Stoitzner P, Brandacher G, et al. Tetrahydro-4-aminobiopterin attenuates dendritic cell-induced T cell priming independently from inducible nitric oxide synthase. J Immunol 2005; 174: 7584.
  • 112
    Zhu KJ, Shen QY, Cheng H, Mao XH, Lao LM, Hao GL. Triptolide affects the differentiation, maturation and function of human dendritic cells. Int Immunopharmacol 2005; 5: 1415.
  • 113
    Rubio MT, Ittelet D, Raymond E, Blay JY, Bernard J, Chouaib S. The immunosuppressive effect of vincristine on allostimulatory potential of human dendritic cells interferes with their function and survival. Int J Oncol 2004; 25: 407.
  • 114
    Van Etten E, Decallonne B, Bouillon R, Mathieu C. NOD bone marrow-derived dendritic cells are modulated by analogs of 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 2004; 457. 8990.
  • 115
    Van Halteren AG, Tysma OM, Van Etten E, Mathieu C, Roep BO. 1 alpha,25-dihydroxyvitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. J Autoimmun 2004; 23: 233.